Deep Longevity acquired by Regent Pacific

Hong Kong public company enters Longevity business by acquiring aging clock specialist Deep Longevity.

Not even two months after it exited stealth to announce its partnership with Human Longevity Inc (HLI), Deep Longevity, an Insilico spin-out, has been snapped up for US$3.79 million by Hong Kong-based Regent Pacific Group, an investment firm specialising in healthcare and late‐stage life sciences.

Longevity.Technology: Biomarkers of aging are one of the current darlings of the Longevity world. There is little point in committing time and money developing therapies that attempt to combat aging if we cannot measure how well they perform. Deep Longevity’s previously-announced partnership with HLI is based on launching the first scalable AI system for aging-related biomarker development and the deployment of that technology worldwide. These objectives should now be accelerated through Regent Pacific’s involvement.

We are excited by the news that Alex Zhavoronkov will step down as the CEO of Deep Longevity to assume a new role of a Chief Longevity Officer (CLO) at the company. Jim Mellon will be Chairman of the combined company and Dr Wei-Wu He will join as Director.

Today’s announcement means that Deep Longevity (DLI) is positioning itself as the gold standard in multi-modal aging clocks. As well having as the largest number of clocks, the company has developed a wealth of experience in building them and applying them to clinical practice.

The combined company is set to refocus on Longevity and intends to build the first Longevity conglomerate working with insurance companies, pharmaceutical companies, healthcare providers and clinics (the proof of concept was previously completed with HLI).

“… the first public company to become the engine for the emerging longevity ecosystem… “

Alex Zhavoronkov, PhD, the founder and CEO of Deep Longevity said: “By becoming part of Regent Pacific, we are planning to help it transform into the first public company to become the engine for the emerging longevity ecosystem and help everyone on the planet live longer and better regardless of their nationality, race, gender, or social status. As part of Regent Pacific, we aim to service the longevity biotechnology industry as well as the health and life insurance industries and become the ultimate instrument to hedge the longevity risk.”

Scientists from Harvard and Insilico have used thousands of whole genome sequencing samples from gut bacteria to develop a new deep microbiomic aging clock
Alex Zhavoronkov, PhD, the founder and CEO of Deep Longevity

Jamie Gibson, Chief Executive Officer of Regent Pacific, said, “Our long-term vision is to transform Regent Pacific into a global end-to-end longevity and wellness biotechnology company dedicated to extending healthy productive lives of billions of people worldwide by developing a longevity ecosystem. It is only logical to start executing on this vision via the acquisition of the most sophisticated AI system designed to track the rate of human aging and evaluate the effectiveness of longevity interventions. This system can be used by the longevity and performance clinics, insurance companies, pharmaceutical companies, and large employers that deeply care about their workforce.”

Longitudinal data, courtesy of Alex Zhavoronkov, CEO, Deep Longevity

DLI is developing explainable and user-friendly AI systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological and psychological levels. It is also working on systems for the emerging field of Longevity medicine, enabling physicians to make better decisions on interventions that may slow down or reverse the aging processes.

DLI has developed its Longevity as a Service (LaaS) solution to integrate multiple deep biomarkers of aging, dubbed “deep aging clocks,” which provide a universal multifactorial measure of human biological age.

Mr Gibson added, “DLI will be run by the most credible experts in aging and longevity with Jim Mellon, the Company’s chairman and the author of “Juvenescence” being joined by other noted biotechnology investors and entrepreneurs including Dr Wei-Wu He, chairman of HLI, and Alex Zhavoronkov, PhD, the founder and CEO of DLI and adjunct professor at the Buck Institute for Research on Aging. Together these individuals will combine their efforts to create a dedicated and focused longevity company.”

Image credit: nextvoyagePixabay